Here are the latest stories being discussed in biopharma today:

Five questions on Lilly’s Alzheimer’s drug

The FDA’s decision to convene a committee of independent experts could delay a ruling on Eli Lilly’s Alzheimer’s drug, donanemab, for months. According to Lilly, regulators are interested in discussing the drug’s safety, its decision to stop treatment once it clears up amyloid plaques, and analyses that suggest levels of the brain protein tau can predict how well a person responds to treatment.

FDA approves weight loss drug Wegovy to reduce cardiovascular events

The FDA expanded the label for Novo Nordisk’s weight loss injection Wegovy, approving it as a treatment to reduce the risk of cardiovascular death, heart attack and stroke in adults with heart disease who are also either obese or overweight.

Akero executives point to advanced fibrosis patients for MASH drug

Akero Therapeutics expects its experimental MASH (metabolic dysfunction-associated steatohepatitis) drug will be used to treat patients with advanced fibrosis if it receives FDA approval.

Pharma bristles at Biden’s State of the Union address

President Joe Biden used his State of the Union address to lay out plans to lower drug costs by expanding the Inflation Reduction Act’s drug price negotiations in Medicare to include 500 drugs over the next 10 years.

No immediate upside for manufacturers due to Novo-Catalent deal, says Samsung Bio exec

Even if competitor manufacturers attract the attention of Catalent’s customers on the back of its being acquired by Novo Holdings, it will take time for rival companies to see any notable client gains, according to Samsung Biologics head of global sales, Kevin Sharp.

Gilead’s oncology campaign highlights metastatic breast cancer patients

Gilead Sciences is focusing on the often overlooked needs of people living with metastatic and triple-negative breast cancer in its latest unbranded oncology campaign. The “Expose MBC” campaign is built on insights from patients who often feel unseen or unheard in the broader breast cancer community.